{"name":"InflaRx GmbH","slug":"inflarx-gmbh","ticker":"","exchange":"","domain":"inflarxgmbh.com","description":"InflaRx GmbH is a clinical-stage biopharmaceutical company focused on developing anti-inflammatory therapies based on the inhibition of C5a, a key mediator of the complement system. The company's lead product, IFX-1, is in Phase 2 clinical trials for various indications, including severe COVID-19 and hidradenitis suppurativa.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CaCP29","genericName":"CaCP29","slug":"cacp29","indication":"Treatment of Hidradenitis Suppurativa","status":"phase_2"}]}],"pipeline":[{"name":"CaCP29","genericName":"CaCP29","slug":"cacp29","phase":"phase_2","mechanism":"CaCP29 is a monoclonal antibody targeting the complement system.","indications":["Treatment of Hidradenitis Suppurativa"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQenpYejVLUWUwUFFZUkM0enJLVjBFb2pOTUpLNG9FNUUxcTJYMHZOOXRqeXJyTWc4ZDdlWTdKTi12ZFhUUDU4VEdNeXJ0Q054RUl1Y3dlNXJGMmlRV0JQZW1uSFlMZE5VNnhyVW1RRWhqbGpnTEF0VnV6NF9oV1NLRzFBSVlpYl94YUZUY3duS3NMT1BlRkpldVM5bk8zSjBTNW1LeDBSYW1SNW11cjE4ZWxqWjFKdFVFNXZIRXotWEZnbU43X0hhZUFmWi1BaEd5N2F2bg?oc=5","date":"2026-03-31","type":"pipeline","source":"Sahm","summary":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Sahm","headline":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-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?oc=5","date":"2026-03-14","type":"pipeline","source":"The Manila Times","summary":"InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - The Manila Times","headline":"InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wSzItdHg3aGFLdkFOUFR4azYtTmtqSXNsekNudVpqaDI3SkEtUTJqRzYzMldhNmhHb2ttT3pzdHY0NWp6N1B5ZEVTTlRDQkJQNk5v?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"IFRX Stock Price, News & Analysis - Stock Titan","headline":"IFRX Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}